Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Jun 15, 2020; 12(6): 651-662
Published online Jun 15, 2020. doi: 10.4251/wjgo.v12.i6.651
Published online Jun 15, 2020. doi: 10.4251/wjgo.v12.i6.651
Table 2 Distribution of pathologic stage groups after surgery, n (%)
| Pathologic stage group | n = 57 |
| Surgery alone | |
| IB | 6 (10.5) |
| IIA | 13 (22.8) |
| IIB | 5 (8.8) |
| IIIA | 2 (3.5) |
| IIIB | 8 (14.0) |
| IVA | 1 (1.8) |
| Neoadjuvant therapy | |
| I | 11 (19.3) |
| II | 1 (1.8) |
| IIIA | 4 (7.0) |
| IIIB | 6 (10.5) |
- Citation: Lin YB, Fu JH, Huang Y, Hu YH, Luo KJ, Wang KX, Bella AÉ, Situ DR, Chen JY, Lin T, D’Journo XB, Novoa NM, Brunelli A, Fernando HC, Cerfolio RJ, Ismail M, Yang H, the AME Thoracic Surgery Collaborative Group. Fibrin sealant for esophageal anastomosis: A phase II study. World J Gastrointest Oncol 2020; 12(6): 651-662
- URL: https://www.wjgnet.com/1948-5204/full/v12/i6/651.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i6.651